Small Cell Lung Cancer (SCLC) antibody

Catalog No. ABIN3026918

Product Details

Target: Small Cell Lung Cancer (SCLC)

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: Immunofluorescence (IF), Immunohistochemistry (Frozen Sections) (IHC (fro))

Characteristics: This mAb reacts with a membrane-associated protein present in normal and malignant neuroendocrine tissues including small cell lung cancer (SCLC). It stains neural and a variable number of endocrine tissues and in the lung it reacts preferentially with SCLC and carcinoids. Its epitope is destroyed during formalin fixation. This antibody was categorized during the First International Workshop on Small Cell Lung Cancer Antigens held in London in April 1987. There are two major types of Lung Carcinoma: non-small cell, which accounts for 80 % of all cases, and small cell, which accounts for roughly 20 % of all lung cancers reported. The lung continues to be a customary place for cancer migration from tumors elsewhere in the body. Treatment depends on the specific cell type of the cancer, level of progression and status of the individual patient.

Purification: Protein G affinity chromatography

Immunogen: Lung Cancer-associated antigen isolated from small cell lung carcinoma-derived cell line was used as the immunogen for the SCLC Marker antibody.

Clone: MOC-52

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal dilution of the SCLC Marker antibody should be determined by the researcher.\. Immunofluorescence: 0.5-1 μg/mL,Immunohistochemistry (Frozen): 0.5-1.0 μg/mL for 30 minutes at RT

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Store the SCLC Marker antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Target Details

Target: Small Cell Lung Cancer (SCLC)

Alternative Name: SCLC Marker

Background: This mAb reacts with a membrane-associated protein present in normal and malignant neuroendocrine tissues including small cell lung cancer (SCLC). It stains neural and a variable number of endocrine tissues and in the lung it reacts preferentially with SCLC and carcinoids. Its epitope is destroyed during formalin fixation. This antibody was categorized during the First International Workshop on Small Cell Lung Cancer Antigens held in London in April 1987. There are two major types of Lung Carcinoma: non-small cell, which accounts for 80 % of all cases, and small cell, which accounts for roughly 20 % of all lung cancers reported. The lung continues to be a customary place for cancer migration from tumors elsewhere in the body. Treatment depends on the specific cell type of the cancer, level of progression and status of the individual patient.